Sakurasaku Plus CoTSE:7097 -0.33%65 EBITDA Margin % is 9.06% as of Jan. 2026, which is 46% below its 10-year median of 16.68. GuruFocus rates TSE:7097 with a GF Score™ of 65/100 and a GF Value™ of 円1,459.55 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Sakurasaku Plus Co ranks worse than 54.29% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sakurasaku Plus Co's EBITDA for the
six
months ended in Jan. 2026 was 円753 Mil. Sakurasaku Plus Co's Revenue for the
six
months ended in Jan. 2026 was 円8,315 Mil. Therefore, Sakurasaku Plus Co's EBITDA margin for the quarter that ended in Jan. 2026 was 9.06%.
Sakurasaku Plus Co (TSE:7097) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sakurasaku Plus Co EBITDA Margin % Related Terms
Sakurasaku Plus Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sakurasaku Plus Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7097 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Sakurasaku Plus Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sakurasaku Plus Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sakurasaku Plus Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sakurasaku Plus Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sakurasaku Plus Co (TSE:7097) has a EBITDA Margin % of 9.06% as of Jan. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sakurasaku Plus Co and its competitors. This is 46% below median its historical median of 16.68. Over the past decade, Sakurasaku Plus Co's EBITDA Margin % has ranged from 6.55 to 29.41. According to the industry distribution chart, Sakurasaku Plus Co ranks #361 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 54.3%.
Is Sakurasaku Plus Co's EBITDA Margin % too high?
Sakurasaku Plus Co's current EBITDA Margin % of 9.06% is 46% below median its 10-year median of 16.68. Over the past 10 years, this metric has ranged from a low of 6.55 to a high of 29.41. The Healthcare Providers & Services industry median EBITDA Margin % is 10.19. Sakurasaku Plus Co's value of 9.06% is 11.1% below this industry median. Based on the distribution chart, Sakurasaku Plus Co ranks #361 out of 665 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sakurasaku Plus Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sakurasaku Plus Co's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Sakurasaku Plus Co ranks #361 out of 665 companies for EBITDA Margin %. This places Sakurasaku Plus Co in the lower half of its industry. The industry median EBITDA Margin % is 10.19. Sakurasaku Plus Co's value of 9.06% is 11.1% below this benchmark. Historically, Sakurasaku Plus Co's own EBITDA Margin % has ranged from 6.55 to 29.41 over the past decade. While the company's 10-year median is 16.68 vs. the industry median of 10.19, Sakurasaku Plus Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.19, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sakurasaku Plus Co's current EBITDA Margin % of 9.06% is 11.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sakurasaku Plus Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sakurasaku Plus Co's current EBITDA Margin % is 9.06%, which is 46% below median its own 10-year median of 16.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sakurasaku Plus Co stock overvalued right now?
Based on GuruFocus' analysis, Sakurasaku Plus Co (TSE:7097) is currently considered Significantly Overvalued. The stock's GF Value™ is 円1,459.55, compared to a current price of 円3,000.00 — trading 105.5% above its estimated fair value. The current EBITDA Margin % is 9.06%, which is 46% below median its 10-year median of 16.68 and 11.1% below the Healthcare Providers & Services industry median of 10.19. Sakurasaku Plus Co's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sakurasaku Plus Co (TSE:7097), the current EBITDA Margin % is 9.06% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sakurasaku Plus Co (TSE:7097) Overvalued in 2026?
Based on GuruFocus' analysis, Sakurasaku Plus Co stock appears to be overvalued.
The current stock price of 円3,000.00 is trading 105.5% above its estimated GF Value™ of 円1,459.55.
GuruFocus considers Sakurasaku Plus Co to be Significantly Overvalued.
Key valuation signals for TSE:7097:
EBITDA Margin %: 9.06% (46% below median its 10-year median of 16.68)
GF Value™: 円1,459.55 vs. price of 円3,000.00 (105.5% above fair value)
Industry Position: 11.1% below the Healthcare Providers & Services median (#361 of 665)
No single metric tells the full story. See the TSE:7097 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sakurasaku Plus Co Ltd is engaged in the operation and use of childcare daycare centers. The company also provides real estate brokerage and management services. The Group operates in a single segment, the children and childcare support business.
65GF Score
Get the complete analysis for TSE:7097
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7097 has been successfully added to your 
